Reports

Global Liposomal Doxorubicin Market to Grow at a CAGR of 6.1% During 2024-2032, Driven by the Rising Health Issues Among Consumers

Sale

Global Liposomal Doxorubicin Market Size, Share, Forecast: By Product: Doxil/Caelyx, Lipodox, Myocet, Others; By Application: Leukaemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Gastric Cancer, Liver Cancer, Kidney Cancer, Multiple Myeloma, Ovarian Cancer, Other Cancers; Regional Analysis; Competitive Landscape; 2024-2032

Global Liposomal Doxorubicin Market Outlook

The global liposomal doxorubicin market attained a value of more than USD 1238.29 million in 2023. The market is further expected to grow in the forecast period of 2024-2032 at a CAGR of 6.1% to reach over USD 2109.60 million by 2032.

Global Liposomal Doxorubicin Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The Rising Prevalence of Ovarian Cancer is Driving the Growth of the Market

The global market for liposomal doxorubicin is expanding owing to an increase in breast and ovarian cancer cases in recent years. In addition to this, the market growth can also be ascribed to an increased awareness of the advantages of liposomal doxorubicin formulations over standard doxorubicin. Despite advances in technology and research, cancer claimed the lives of several people in 2008.

The treatment of breast cancer, thyroid cancer, and pancreatic cancer have all seen substantial advancements in technology and drugs/vaccines, resulting in higher survival rates. Liposomal doxorubicin is one of a new family of medication formulations that are administered in liposomes, which are small vesicles which has taken over the market lately, thereby pushing the market growth.

North America is Expected to Hold a Significant Share in the Overall Market

North America is projected to account for a substantial percentage of global revenue in the market. This can be attributed to the high prevalence of ovarian, breast, and liver cancers, as well as a number of other malignancies in the region. Furthermore, the region's growth is fuelled by the existence of superior healthcare facilities and newer medications such as liposomal doxorubicin. Moreover, high level of patient awareness of the many therapies available in the market is another factor, which boosts the market growth in the region. The market growth in North America is further positively influenced by the robust reimbursement and regulatory framework.

Liposomal Doxorubicin: Definition and Segmentation

Liposomal doxorubicin is an anti-cancer chemotherapy drug. Also known by the brand names Caelyx or Myocet, liposomal doxorubicin is used for the treatment of different cancers, including breast cancer, ovarian cancer, and gastric cancer, among others.

Global Liposomal Doxorubicin Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on product, the market can be divided into:

Doxil/Caelyx
Lipodox
Myocet
Others

The market can be broadly categorised on the basis of its application as:

Leukaemia
Bone Sarcoma
Breast Cancer
Endometrial Cancer
Gastric Cancer
Liver Cancer
Kidney Cancer
Multiple Myeloma
Ovarian Cancer
Other Cancers

The EMR report looks into the regional markets of liposomal doxorubicin like North America, Europe, the Asia Pacific, the Middle East Africa, and Latin America.

Global Liposomal Doxorubicin Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rapid Cases of Breast Carcinoma is Expected to Boost the Market Growth

Breast cancer has been rising at an alarming rate across various countries, which makes liposomal doxorubicin one of its major applications. One of the primary aspects boosting the drug's popularity and usage to treat breast cancer is the growing innovation in formulations. These are some of the factors furthering the growth of the market. In addition, some of the drivers expected to propel the market in the coming years are increased use of chemotherapy treatments, rising demand for targeted therapy drugs, and increased investment by private firms to cater to this application. Furthermore, government funding towards the healthcare sector is also one of the important factors for widening the market’s reach globally.

Key Industry Players in the Global Liposomal Doxorubicin Market

The report presents a detailed analysis of the following key players in the global liposomal doxorubicin market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

Pfizer, Inc
Sun Pharmaceutical Industries Ltd.
Cipla, Inc.
Teva Pharmaceuticals Industries Ltd.
Janssen Products, LP
Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report

REPORT FEATURES	DETAILS
Base Year	2023
Historical Period	2017-2023
Forecast Period	2024-2032
Scope of the Report	Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment: Product Application Region
Breakup by Product	Doxil/Caelyx Lipodox Myocet Others
Breakup by Application	Leukaemia Bone Sarcoma Breast Cancer Endometrial Cancer Gastric Cancer Liver Cancer Kidney Cancer Multiple Myeloma Ovarian Cancer Other Cancers
Breakup by Region	North America United States of America Canada Europe United Kingdom Germany France Italy Others Asia Pacific China Japan India ASEAN Australia Others Latin America Brazil Argentina Mexico Others Middle East and Africa Saudi Arabia United Arab Emirates Nigeria South Africa Others
Market Dynamics	SWOT Analysis Porter's Five Forces Analysis Key Indicators for Demand Key Indicators for Price
Competitive Landscape	Market Structure Company Profiles Company Overview Product Portfolio Demographic Reach and Achievements Certifications
Companies Covered	Pfizer, Inc Sun Pharmaceutical Industries Ltd. Cipla, Inc. Teva Pharmaceuticals Industries Ltd. Janssen Products, LP Others
Report Price and Purchase Option	Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format	Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1   Preface
2   Report Coverage – Key Segmentation and Scope
3   Report Description
   3.1   Market Definition and Outlook
   3.2   Properties and Applications
   3.3   Market Analysis
   3.4   Key Players
4   Key Assumptions
5   Executive Summary
   5.1   Overview
   5.2   Key Drivers
   5.3   Key Developments
   5.4   Competitive Structure
   5.5   Key Industrial Trends
6   Snapshot
   6.1   Global
   6.2   Regional
7   Opportunities and Challenges in the Market
8   Global Liposomal Doxorubicin Market Analysis
   8.1   Key Industry Highlights
   8.2   Global Liposomal Doxorubicin Historical Market (2018-2023)
   8.3   Global Liposomal Doxorubicin Market Forecast (2024-2032)
   8.4   Global Liposomal Doxorubicin Market by Product
       8.4.1   Doxil/Caelyx
           8.4.1.1 Historical Trend (2018-2023)
           8.4.1.2 Forecast Trend (2024-2032)
       8.4.2   Lipodox
           8.4.2.1 Historical Trend (2018-2023)
           8.4.2.2 Forecast Trend (2024-2032)
       8.4.3   Myocet
           8.4.3.1 Historical Trend (2018-2023)
           8.4.3.2 Forecast Trend (2024-2032)
       8.4.4   Others
   8.5   Global Liposomal Doxorubicin Market by Application
       8.5.1   Leukaemia
           8.5.1.1 Historical Trend (2018-2023)
           8.5.1.2 Forecast Trend (2024-2032)
       8.5.2   Bone Sarcoma
           8.5.2.1 Historical Trend (2018-2023)
           8.5.2.2 Forecast Trend (2024-2032)
       8.5.3   Breast Cancer
           8.5.3.1 Historical Trend (2018-2023)
           8.5.3.2 Forecast Trend (2024-2032)
       8.5.4   Endometrial Cancer
           8.5.4.1 Historical Trend (2018-2023)
           8.5.4.2 Forecast Trend (2024-2032)
       8.5.5   Gastric Cancer
           8.5.5.1 Historical Trend (2018-2023)
           8.5.5.2 Forecast Trend (2024-2032)
       8.5.6   Liver Cancer
           8.5.6.1 Historical Trend (2018-2023)
           8.5.6.2 Forecast Trend (2024-2032)
       8.5.7   Kidney Cancer
           8.5.7.1 Historical Trend (2018-2023)
           8.5.7.2 Forecast Trend (2024-2032)
       8.5.8   Multiple Myeloma
           8.5.8.1 Historical Trend (2018-2023)
           8.5.8.2 Forecast Trend (2024-2032)
       8.5.9   Ovarian Cancer
           8.5.9.1 Historical Trend (2018-2023)
           8.5.9.2 Forecast Trend (2024-2032)
       8.5.10   Other Cancers
   8.6   Global Liposomal Doxorubicin Market by Region
8.6.1 North America
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Europe
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Asia Pacific
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.6.4 Latin America
8.6.4.1 Historical Trend (2018-2023)
8.6.4.2 Forecast Trend (2024-2032)
8.6.5 Middle East and Africa
8.6.5.1 Historical Trend (2018-2023)
8.6.5.2 Forecast Trend (2024-2032)
9 North America Liposomal Doxorubicin Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Liposomal Doxorubicin Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Liposomal Doxorubicin Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Liposomal Doxorubicin Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Liposomal Doxorubicin Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 Pfizer, Inc.
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Sun Pharmaceutical Industries Ltd.
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Cipla, Inc.
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Teva Pharmaceuticals Industries Ltd.
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Janssen Products, LP
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Others
16 Key Trends and Developments in the Market

List of Key Figures and Tables

1.   Global Liposomal Doxorubicin Market: Key Industry Highlights, 2018 and 2032
2.   Global Liposomal Doxorubicin Historical Market: Breakup by Product (USD Million), 2018-2023
3.   Global Liposomal Doxorubicin Market Forecast: Breakup by Product (USD Million), 2024-2032
4.   Global Liposomal Doxorubicin Historical Market: Breakup by Application (USD Million), 2018-2023
5.   Global Liposomal Doxorubicin Market Forecast: Breakup by Application (USD Million), 2024-2032
6.   Global Liposomal Doxorubicin Historical Market: Breakup by Region (USD Million), 2018-2023
7.   Global Liposomal Doxorubicin Market Forecast: Breakup by Region (USD Million), 2024-2032
8.   North America Global Liposomal Doxorubicin Historical Market: Breakup by Country (USD Million), 2018-2023
9.   North America Global Liposomal Doxorubicin Market Forecast: Breakup by Country (USD Million), 2024-2032
10.   Europe Global Liposomal Doxorubicin Historical Market: Breakup by Country (USD Million), 2018-2023
11.   Europe Global Liposomal Doxorubicin Market Forecast: Breakup by Country (USD Million), 2024-2032
12.   Asia Pacific Global Liposomal Doxorubicin Historical Market: Breakup by Country (USD Million), 2018-2023
13.   Asia Pacific Global Liposomal Doxorubicin Market Forecast: Breakup by Country (USD Million), 2024-2032
14.   Latin America Global Liposomal Doxorubicin Historical Market: Breakup by Country (USD Million), 2018-2023
15.   Latin America Global Liposomal Doxorubicin Market Forecast: Breakup by Country (USD Million), 2024-2032
16.   Middle East and Africa Global Liposomal Doxorubicin Historical Market: Breakup by Country (USD Million), 2018-2023
17.   Middle East and Africa Global Liposomal Doxorubicin Market Forecast: Breakup by Country (USD Million), 2024-2032
18.   Global Liposomal Doxorubicin Market Structure

Key Questions Answered in the Report

What was the global liposomal doxorubicin market size in 2023?

The global liposomal doxorubicin market attained a value of more than USD 1238.29 million in 2023.

What is the growth rate of the market?

The market is projected to grow at a CAGR of 6.1% between 2024 and 2032.

What is the forecast outlook of the market for 2024-2032?

The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach over USD 2109.60 million by 2032.

What are the major industry drivers?

The increase in breast and ovarian cancer cases, as well as increased awareness of the advantages of liposomal doxorubicin formulations over standard doxorubicin has been aiding the market growth.

What are the key industry trends of the global liposomal doxorubicin market?

The market is expected to be defined by the ongoing technological advancements in the industry.

What are the major regional markets of liposomal doxorubicin, according to the EMR report?

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

What are the different products available in the market?

The different products available in the market are doxil/caelyx, lipodox, and myocet, among others.

What are the different applications of liposomal doxorubicin?

The different applications of liposomal doxorubicin include leukaemia, bone sarcoma, breast cancer, endometrial cancer, gastric cancer, liver cancer, kidney cancer, multiple myeloma, and ovarian cancer, among other cancers.

Who are the key industry players, according to the report?

The major players in the industry are Pfizer, Inc, Sun Pharmaceutical Industries Ltd., Cipla, Inc., Teva Pharmaceuticals Industries Ltd, and Janssen Products, LP, among others.

Analyst Review

The global liposomal doxorubicin market attained a value of more than USD 1238.29 million in 2023, driven by the increase in breast and ovarian cancer cases, as well as increased awareness of the advantages of liposomal doxorubicin formulations. The market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 6.1%. The market is projected to reach over USD 2109.60 million by 2032.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its product type, the liposomal doxorubicin industry can be segmented into doxil/caelyx, lipodox, and myocet, among others. On the basis of its application, the industry is divided into leukaemia, bone sarcoma, breast cancer, endometrial cancer, gastric cancer, liver cancer, kidney cancer, multiple myeloma, and ovarian cancer, among other cancers. The major regional markets for liposomal doxorubicin are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Pfizer, Inc, Sun Pharmaceutical Industries Ltd., Cipla, Inc., Teva Pharmaceuticals Industries Ltd, and Janssen Products, LP, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Request Sample

Purchase Full Report

Mini Report

$ ~~2969~~ $2699

Selected Sections, One User
Printing Not Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Single User License

$ ~~5499~~ $4999

All Sections, One User
One Print Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Five User License

$ ~~6599~~ $5999

All Sections, Five Users
Five Prints Allowed
Email Delivery in PDF
Free Limited Customisation
Post Sales Analyst Support
~~50% Discount on Next Update~~

Buy Now

Corporate License

$ ~~7699~~ $6999

All Sections, Unlimited Users
Unlimited Prints Allowed
Email Delivery in PDF + Excel
Free Limited Customisation
Post Sales Analyst Support
50% Discount on Next Update

Buy Now

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER